Consensus nomenclature for in vivo imaging of reversibly binding radioligands

Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson

doi:10.1038/sj.jcbfm.9600493

Consensus nomenclature for in vivo imaging of reversibly binding radioligands

J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9. doi: 10.1038/sj.jcbfm.9600493. Epub 2007 May 9.

Affiliation

¹ National Institute of Mental Health, Molecular Imaging Branch, Bethesda, Maryland, USA. robert.innis@nih.gov

PMID: 17519979
DOI: 10.1038/sj.jcbfm.9600493

Abstract

An international group of experts in pharmacokinetic modeling recommends a consensus nomenclature to describe in vivo molecular imaging of reversibly binding radioligands.

Publication types

Review

MeSH terms

Consensus
Diagnostic Imaging / standards*
Positron-Emission Tomography
Radioligand Assay / standards*
Radiopharmaceuticals*
Terminology as Topic*
Tomography, Emission-Computed, Single-Photon

Substances

Radiopharmaceuticals